Leerink Partnrs Predicts Allakos FY2029 Earnings

Allakos Inc. (NASDAQ:ALLK) – Equities researchers at Leerink Partnrs issued their FY2029 earnings per share estimates for Allakos in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will earn ($0.20) per share for the year. The consensus estimate for Allakos’ current full-year earnings is ($1.16) per share.

Several other brokerages also recently weighed in on ALLK. Citizens Jmp downgraded Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Piper Sandler lowered shares of Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Allakos currently has an average rating of “Hold” and a consensus price target of $2.00.

Allakos Price Performance

NASDAQ:ALLK opened at $0.27 on Thursday. Allakos has a 1-year low of $0.23 and a 1-year high of $1.69. The firm has a 50 day simple moving average of $0.96 and a 200-day simple moving average of $0.88.

Allakos (NASDAQ:ALLK) last released its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01.

Hedge Funds Weigh In On Allakos

Several hedge funds and other institutional investors have recently made changes to their positions in ALLK. Cubist Systematic Strategies LLC purchased a new position in shares of Allakos in the second quarter valued at $55,000. GSA Capital Partners LLP boosted its position in Allakos by 11.9% in the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after buying an additional 84,750 shares during the last quarter. FMR LLC grew its stake in shares of Allakos by 14.6% during the third quarter. FMR LLC now owns 5,370,247 shares of the company’s stock valued at $3,508,000 after acquiring an additional 685,623 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Allakos during the third quarter worth about $1,143,000. Finally, RBF Capital LLC lifted its stake in shares of Allakos by 45.9% in the third quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after acquiring an additional 160,529 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.